Insulet (PODD) EBIT Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn |
| 10 | Insulet | 10.37 Bn | 9.89 Bn | 529.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 49.59% |
| Dec 31, 2025 | 85.63% |
| Sep 30, 2025 | 37.67% |
| Jun 30, 2025 | 34.51% |
| Mar 31, 2025 | 63.93% |
| Dec 31, 2024 | 43.28% |
| Sep 30, 2024 | 38.96% |
| Jun 30, 2024 | 48.29% |
| Mar 31, 2024 | 50.78% |
| Dec 31, 2023 | 45.68% |
| Sep 30, 2023 | 51.51% |
| Jun 30, 2023 | 48.37% |
| Dec 31, 2022 | 100.74% |
| Sep 30, 2022 | 7.22% |
| Jun 30, 2022 | -51.39% |
| Mar 31, 2022 | 55.66% |
| Dec 31, 2021 | 69.57% |
| Sep 30, 2021 | 69.37% |
| Jun 30, 2021 | 86.26% |
| Mar 31, 2021 | 32.71% |
| Dec 31, 2020 | 10.37% |
| Sep 30, 2020 | 29.26% |
| Jun 30, 2020 | 31.66% |
| Mar 31, 2020 | 24.84% |
| Dec 31, 2019 | 73.00% |
| Sep 30, 2019 | 51.23% |
| Jun 30, 2019 | 28.03% |
| Mar 31, 2019 | 42.47% |
| Dec 31, 2018 | 139.50% |
| Sep 30, 2018 | 19.10% |
| Jun 30, 2018 | 22.36% |
| Dec 31, 2017 | 33.90% |
| Sep 30, 2017 | 17.52% |
| Jun 30, 2017 | 20.42% |
| Mar 31, 2017 | 13.40% |
| Dec 31, 2016 | 17.02% |
| Sep 30, 2016 | 17.58% |
| Jun 30, 2016 | 38.73% |
| Mar 31, 2016 | -1.14% |
| Dec 31, 2015 | -5.34% |
| Sep 30, 2015 | -12.31% |
| Jun 30, 2015 | -7.27% |